23 percent of pharmacies selling imatinib online did not include drug-related warnings on their websites
TUESDAY, Aug. 2, 2022 (HealthDay News) — Many online pharmacies sell imatinib without requiring a prescription, and nearly one-quarter do not include warnings related to imatinib, according to a study published in the July issue of the Journal of the National Comprehensive Cancer Network.
Yujiao Sun, Pharm.D., from the University of North Carolina in Chapel Hill, and colleagues examined the accessibility of imatinib through online pharmacies and analyzed each website for medication safety, price, and marketing tactics.
Forty-four online pharmacies were identified: Only three (7 percent) were certified and the rest were classified as rogue, unapproved, or unclassified (23, 13, and five [52, 30, and 11 percent], respectively). The researchers found that 13 online pharmacies sold imatinib without a prescription. Ten online pharmacies selling imatinib did not include drug-related warnings on their websites, and 21 did not limit the quantity that could be purchased. Thirty-four of the pharmacies did not offer pharmacist consultations; however, nearly all websites (91 percent) extended offers to speak with sales associates. Most online pharmacies (95 percent) claimed price discounts; only 23 and 34 percent provided bulk discounts or coupons, respectively. Of the rogue pharmacies, one-third (seven) claimed to be registered or accredited on their websites.
“Providers should be aware of easy access to oral oncolytics online and be sure to educate and assist patients in obtaining medications through safe and legitimate sources,” the authors write.
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
Personalized Support Boosts Families" Genetic Testing for Hereditary Cancers
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
Age-, Joint-Specific Ultrasound Reference Values Set for Healthy Joints
2013 to 2024 Saw Decrease in Benzodiazepine Prescribing
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria